Highlights for the quarter ended 30 June 2017
• Revenue increased by 474% compared to Q2 2016; driven by 343% unit sales growth
• Unit growth of 145% as compared to Q1 2017
• Revenue contribution from new sites in the United States ahead of plan
• AeroForm® available in more than one hundred (100) hospitals across the US
• Increased average unit selling price (ASP) in US market as compared to Q1 2017
• Cash and short-term investments balance as of 30 June 2017 of US$27.2 million
Palo Alto, CA, United States – AirXpanders, Inc. (ASX:AXP), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, today released its Appendix 4C – Quarterly Cash Flow report for the quarter ended 30 June 2017.
For further information please download PDF attached:
Download this document
